Department of Dermatology, University of Zurich, Zurich, Switzerland.
Swiss Med Wkly. 2010 Feb 6;140(5-6):85-91. doi: 10.4414/smw.2010.12756.
Evaluation of the current clinical treatment of psoriasis in Switzerland remains to be measured with the parameters cost-of-illness and quality of life.
To obtain data on out-of-pocket expenses, costs of outpatient/office-based care and inpatient care for psoriasis, and to extrapolate total costs by state of severity to the entire Swiss population.
1200 retrospective surveys were distributed to patient members of the Swiss Psoriasis and Vitiligo Society, and 400 surveys to office-/hospital-based Swiss dermatologists. The reference year for data collection was 2005. Patients were stratified into three subgroups according to severity of disease. Costs of inpatient care were measured by the amount of hospital days of psoriatic patients from the Swiss Federal Hospital Statistics.
383 patient questionnaires, and 170 cases documented by 57 dermatologists were analyzed. Out-of-pocket expenses/costs for ambulatory care per patient and year ranged from CHF 600-1100 for mild psoriasis to CHF 2400-9900 for severe psoriasis. Including costs for inpatient care of approximately CHF 60 million, the total annual costs for psoriasis in Switzerland in 2004/5 amounted to approximately CHF 314-458 million.
Moderate-to-severe psoriasis is associated with a significant impact on the quality of life and at least 4-fold higher costs than mild psoriasis, indicating the need for efficient control of the disease. This cost-of-illness study provides specific health economic data for future healthcare decision making, particularly with the advent of new therapeutic agents for effective psoriasis control.
评估瑞士目前针对银屑病的临床治疗方法需要采用疾病成本和生活质量这两个参数。
获得银屑病患者自付费用、门诊/基于办公室的护理和住院护理费用的数据，并通过严重程度对各州进行推断，从而将总费用外推至整个瑞士人群。
向瑞士银屑病和白癜风协会的患者成员分发了 1200 份回顾性调查，向基于办公室/医院的瑞士皮肤科医生分发了 400 份调查。数据收集的参考年份为 2005 年。根据疾病严重程度将患者分为三个亚组。通过瑞士联邦医院统计数据中银屑病患者的住院天数来衡量住院护理费用。
分析了 383 份患者问卷和 57 位皮肤科医生记录的 170 例病例。轻度银屑病患者的门诊/年度自付费用/护理费用为每患者 CHF600-1100，重度银屑病患者为 CHF2400-9900。包括大约 CHF6000 万的住院护理费用在内，2004/5 年瑞士银屑病的年总费用约为 3.14 亿至 4.58 亿瑞士法郎。
中重度银屑病对生活质量有重大影响，其费用比轻度银屑病高至少 4 倍，表明需要对疾病进行有效的控制。这项疾病成本研究为未来医疗保健决策提供了具体的健康经济学数据，特别是随着新型治疗药物的出现，可有效控制银屑病。
